New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
This was a prospective, randomised, double-blind, double-dummy, parallel-group, multicentre study conducted in 36 primary-care centres in Sweden in accordance with the 1996 Declaration of Helsinki.
GlaxoSmithKline has received approval in Japan for its key respiratory product Seretide/Advair Diskus and its anti-thrombotic Arixtra, a move which the company says should make a significant ...
Results of the European INSPIRE (Investigating New Standards for Prophylaxis in Reduction of Exacerbations) study, published in the American Journal of Respiratory and Critical Care Medicine (2008: ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Mar 14, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Advair Diskus 250/50 is the approved dose for treatment of COPD in the US. Advair Diskus 500/50 is not approved for use in COPD in the US. About COPD Chronic obstructive pulmonary disease (COPD) is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback